The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
177Lu‐[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy
Open accessAbstract
BACKGROUND: 177 Lu‐(DOTA0,Tyr3) octreotate is a new treatment modality for disseminated neuroendocrine tumors. According to a consensus protocol, the calculated maximally tolerated absorbed dose to the kidney should not exceed 27 Gy. In commonly used dosimetry methods, planar imaging is used for determination of the residence time, whereas the kidney mass is determined from a computed tomography (CT) scan. METHODS: Three different quantification methods were used to evaluate the absorbed dose to the kidneys. The first method involved common planar activity imaging, and the absorbed dose was calculated using the medical internal radiation dose (MIRD) formalism, using CT scan‐based kidney masses. For this method, 2 region of interest locations for the background correction were investigated. The second method also included single‐photon emission computed tomography (SPECT) data, which were used to scale the amplitude of the time‐activity curve obtained from planar images. The absorbed dose was calculated as in the planar method. The third method used quantitative SPECT images converted to absorbed dose rate images, where the median absorbed dose rate in the kidneys was calculated in a volume of interest defined over the renal cortex. RESULTS: For some patients, the results showed a large difference in calculated kidney‐absorbed doses, depending on the dosimetry method. The 2 SPECT‐based methods generally gave consistent values, although the calculations were based on different assumptions. Dosimetry using the baseline planar method gave higher absorbed doses in all patients. The values obtained from planar imaging with a background region of interest placed adjacent to the kidneys were more consistent with dosimetry also including SPECT. For the accumulated tumor absorbed dose, the first 2 of the 4 planned therapy cycles made the major contribution. CONCLUSIONS: The results suggested that patients evaluated according to the conventional planar‐based dosimetry method may have been undertreated compared with the other methods. Hematology and creatinine did not indicate any restriction for a more aggressive approach, which would be especially useful in patients with more aggressive tumors where there is not time for more protracted therapy. Cancer 2010;116(4 suppl):1084–92. © 2010 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127
Cited by
Violet, J., Jackson, P., Ferdinandus, J., Sandhu, S., Akhurst, T., Iravani, A., Kong, G., Kumar, A. R., Thang, S. P., Eu, P., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.219352 · Cited by 504
Dewaraja, Y. K., Frey, E. C., Sgouros, G., Brill, A. B., Roberson, P., Zanzonico, P. B., & Ljungberg, M. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.100123 · Cited by 419
Self-citationProduction of 177Lu for Targeted Radionuclide Therapy: Available Options
Dash, A., Pillai, M. R. A., & Knapp, F. F. (2015) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-014-0315-z · Cited by 386
Ljungberg, M., Celler, A., Konijnenberg, M. W., Eckerman, K. F., Dewaraja, Y. K., & Sjögreen-Gleisner, K. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.159012 · Cited by 369
Self-citationHicks, R. J., Kwekkeboom, D. J., Krenning, E., Bodei, L., Grozinsky-Glasberg, S., Arnold, R., Borbath, I., Cwikla, J., Toumpanakis, C., Kaltsas, G., et al. (2017) · Neuroendocrinology · doi:10.1159/000475526 · Cited by 336
Metadata
- Authors
- Garkavij, M., Nickel, M., Sjögreen‐Gleisner, K., Ljungberg, M., Ohlsson, T., Wingårdh, K., Strand, S., & Tennvall, J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2010-02-02
- Volume
- 116
- Issue
- S4
- Pages
- 1084-1092
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2017183061
- Cited by
- 205
- References
- 1
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 177Lu‐[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy. https://app.cochat.ai/papers/10.1002/cncr.24796
- The paper
- Garkavij, M., Nickel, M., Sjögreen‐Gleisner, K., Ljungberg, M., Ohlsson, T., Wingårdh, K., Strand, S., & Tennvall, J. (2010). 177Lu‐[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy. Cancer. https://doi.org/10.1002/cncr.24796
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.